FIELD: biotechnology.
SUBSTANCE: disclosed is a method of treating skin lesions and pruritus in a subject with chronic pruritus (CP), including prurigo nodosum. Method involves administering to a subject an effective amount of nemolizumab. Also disclosed are pharmaceutical compositions for treating pruritus in a subject with CP, comprising nemolizumab, and use of nemolizumab in the manufacture of a drug for treating skin lesions and pruritus in a subject with CP.
EFFECT: invention can find further application in therapy.
54 cl, 29 dwg, 7 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR INCREASING NUMBER OF LYMPHOCYTES IN TUMOURS USING HYBRID PROTEIN IL-7 | 2020 |
|
RU2822396C1 |
| TREATMENT OF MUSCULAR WEAKNESS WITH ALKALINE PHOSPHATASES | 2017 |
|
RU2754558C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF PREVENTION AND TREATMENT OF LYSOSOMAL ENZYME DEFICIENCY IN SUBJECT WITH TYPE II MUCOPOLYSACCHARIDOSIS | 2023 |
|
RU2814280C1 |
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| METHODS OF TREATING PATHOLOGICAL CONDITIONS WITH ANTIBODIES WHICH BIND TO THE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2013 |
|
RU2718751C2 |
| A NEW COMBINATION FOR USE IN THE TREATMENT OF MALIGNANT NEOPLASMS | 2016 |
|
RU2742494C2 |
| METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCT TARGETING HER2 FOR TREATING BILE DUCT CANCER | 2019 |
|
RU2819802C2 |
| USE OF COMBINATION OF ANTIBODY TO PD-1 AND VEGFR INHIBITOR IN PRODUCTION OF DRUG FOR TREATMENT OF MALIGNANT NEOPLASMS | 2017 |
|
RU2762746C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
